Veracyte, Inc.
VCYT
Rang in Aktien
#4231
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Aktienkurs
$46.05
Zuletzt synchronisiert: 2026-10-21
Marktkapitalisierung
$3.70B
Veränderung (1 Tag)
2.81%
Veränderung (1 Jahr)
32.51%
Land
US
Handel Veracyte, Inc. (VCYT)
Kategorie
Healthcare
Kursverlauf für Veracyte, Inc. (VCYT)
Höchster Schlusskurs: $44.47 am 2026-10-01
Niedrigster Schlusskurs: $12.82 am 2013-10-01
Niedrigster Schlusskurs: $12.82 am 2013-10-01
Kursverlauf der Aktie von Veracyte, Inc. von 2013 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | -2.90% |
| 2025 | 3.85% |
| 2024 | 55.02% |
| 2023 | 1.26% |
| 2022 | -33.63% |
| 2021 | -25.42% |
| 2020 | 88.25% |
| 2019 | 137.21% |
| 2018 | 87.23% |
| 2017 | -13.42% |
| 2016 | 5.54% |
| 2015 | -8.13% |
| 2014 | -43.76% |
| 2013 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $694.53 | 22.45% |
US
|
|
| $234.00 | 7.29% |
US
|
|
| $416.01 | 121.26% |
US
|
|
| $21.16 | 49.45% |
CN
|
|
| $177.93 | 21.98% |
US
|
